Prosight Management, LP Catalyst Biosciences, Inc. Transaction History

Prosight Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$4.55 - $7.29 $1.37 Million - $2.2 Million	-301,678 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.22 - $6.04 $226,310 - $323,913	53,628 Added 21.62%	301,678 $1.3 Million
Q2 2020 Aug 14, 2020	SELL	$3.76 - $8.01 $507,036 - $1.08 Million	-134,850 Reduced 35.22%	248,050 $1.46 Million
Q1 2020 May 15, 2020	SELL	$3.5 - $8.51 $31,479 - $76,538	-8,994 Reduced 2.3%	382,900 $1.67 Million
Q4 2019 Feb 14, 2020	SELL	$4.52 - $7.91 $751,517 - $1.32 Million	-166,265 Reduced 29.79%	391,894 $2.67 Million
Q3 2019 Nov 14, 2019	BUY	$4.91 - $9.31 $54,338 - $103,033	11,067 Added 2.02%	558,159 $2.74 Million
Q2 2019 Aug 14, 2019	BUY	$7.08 - $10.6 $445,275 - $666,655	62,892 Added 12.99%	547,092 $4.03 Million
Q1 2019 May 15, 2019	BUY	$7.67 - $9.96 $132,691 - $172,308	17,300 Added 3.71%	484,200 $3.93 Million
Q4 2018 Feb 14, 2019	BUY	$6.59 - $11.28 $1.52 Million - $2.6 Million	230,342 Added 97.37%	466,900 $3.68 Million
Q3 2018 Nov 15, 2018	BUY	$9.35 - $12.44 $2.21 Million - $2.94 Million	236,558 New	236,558 $2.55 Million

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.